Please wait...

You selected inventions in category Biology

  • Nanoparticles Of Cerium Oxide Targeted To An Amyloid-Beta Antigen Of Alzheimers Disease And Associated MethodsNanoparticles Of Cerium Oxide Targeted To An...

      Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.

      Full details Contact close
    • A new drug for the prevention and treatment of human influenza A virus IAV human metapneumovirus hMPV and human rhinoviruses HRVA new drug for the prevention and treatment of...

        Potential drug: a modified polyallylamine derivative

        Application: prevention and treatment of human influenza A virus (IAV), human metapneumovirus (hMPV) and human rhinoviruses (HRV)

        Influenza is an acute infectious disease caused by viruses belonging to the Orthomyxoviridae family, and classified into three types: A, B and C. This classification is based on antigenic differences between the major virion proteins, e.g. M protein and nucleoprotein NP. These types differ in terms of epidemiological properties.

        Influenza A virus (IAV) causes acute and chronic respiratory infections. It is a major respiratory pathogen of humans and animals. A period of frequent influenza infections occurs each winter (seasonal flu, the highest incidence occurring
        in January/February). Only type A influenza virus causes epidemics and pandemics because of antigenic shift that is multiple changes in the various genome segments resulting from reassortment of different strains of the virus.

        According to the World Health Organization (WHO) infections with influenza
        and influenza-like viruses occur globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The most severe infections develop in children under two years of age, in the elderly aged 65 or older and in those with compromised immunity. WHO recommends vaccination against the influenza virus as the most effective way to prevent infections. On the other hand, because of a large variability of the virus, the difficulty in obtaining sufficient number of vaccines before the epidemic wave, and not always satisfactory efficacy of the vaccine and anti – influenza drugs, the disease still represents an important medical and epidemiological problem. Therefore, new effective drugs for the anti-influenza treatment are needed.

        The new invention of the Jagiellonian University, which is the subject
        of the proposed offer, discloses a new drug for the treatment of human A virus (IAV) infection.

        Human metapneumovirus (hMPV) was identified in 2001, however, it was proved that infections with this pathogen have occurred in the human population for
        at least 50 years now. It is the only known Pneumovirus which infects humans and causes both upper and lower respiratory tract infections. Respiratory infections caused by hMPV have been reported in patients of every age and gender,
        but children under 5 years are most likely to be susceptible to infections caused
        by hMPV. The clinical manifestations of hMPV disease are flu-like symptoms such
        as runny nose, cough, sore throat and high fever. The virus is widespread, and is found on all continents. Late winter and early spring is the epidemic peak of hMPV infections. More serious symptoms, including severe lower respiratory tract infections, are found mainly in young children and infants under 5 years
        of age, elderly individuals above 60 years of age, and immunocompromised patients, whereas immunocompetent adults present mostly flu-like illnesses or cold symptoms.
        So far, no other drug has been approved for inhibition and prevention
        of infections caused by hMPV. By 2012, the only drugs with broad spectrum
        of activity (such as ribavirin and immunoglobulins) have been used to treat very acute, severe hMPV infections of patients after lung transplantation. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of human metapneumovirus (hMPV) infection.

        The human rhinovirus (HRV) belongs to the smallest known viruses (their diameter does not exceed 30 nm). During the year, particularly in winter and spring, it causes infections of the upper respiratory tract with humans, appearing as the common cold. Rhinoviruses also cause otitis media, sinusitis and inflammations of the lower respiratory tract, including bronchi

        Full details Contact close
      • Novel antiviral agent based on modified chitosanNovel antiviral agent based on modified chitosan

           Medical background: Coronaviruses (CoV) cause many diseases in humans
          and animals; in particular, human pathogens include HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1 and SARS-CoV. The latter causes a condition called Severe Acute Respiratory Syndrome (SARS) – an atypical pneumonia that first appeared in China in 2002. Until now, no effective cure for SARS has been introduced into the clinic, and the treatment of that disease is merely symptomatic. Viruses of this group are also responsible for serious diseases in animals. This fact is important not only in terms of the risk of transmission into human population (the SARS case), but also – in the case of farming animals – for economic reasons.
           Potential antiviral agent: modified natural polysaccharides (chitosan polymer).
           Application: treatment and prevention of viral infections caused by coronaviruses in humans, including respiratory diseases manifested by impaired respiratory function.
           Key features:
          • Development stage: preclinical phase.
          • IP status: several international patent application: EPO, USA, Canada, Japan, China, India (November, 2014).
          • Confirmed ability to efficient bind of coronaviruses and inhibit their replication in vitro and/or ex vivo.
          • Modified chitosan has antibacterial and antifungal activity, which is
          an additional advantage of the offered polymer.
          • The possibility to apply as a solution or spray administrated either topically to the upper respiratory tract (throat, nose, bronchial tree), orally in the case of gastrointestinal infections or intravenously for systemic therapy.

          Licensor information
          The Jagiellonian University, located in Kraków, Poland, is one of the oldest universities in Europe. The offered inventions have been developed by researchers of the Faculty of Chemistry and Faculty of Biochemistry, Biophysics
          and Biotechnology of the Jagiellonian University.

          Full details Contact close

            Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

            Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

            The main advantages of the offered drug are:
             confirmed ability to efficient bind of herpes simplex virus (HSV-1)
            and inhibit its replication in vitro,
             low-toxicity of the drug in vitro,
             the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

            The offered invention is subject of a patent application. Further research
            and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

            More information:
            PhD Klaudia Polakowska – Technology Transfer Officer
            phone. +48 12 663 3832, +48 519 329 129,

            Full details Contact close
          • BiotecnologyBiotecnology

              Bioprotein (Moscow), in partnership with Russia's leading research centers (Ryazan State Agricultural Academy named after P. A. Kostychev, All-Russian Research Institute of Food Biotechnology, Department of Biotechnology of Moscow State University, All-Russian Research Institute of Starch Products, D. Mendeleev University of Chemical Technology of Russia, among others), has developed a non-waste technology for converting Distiller's Dried Grains with Solubles (DDGS) into high-quality feed bio-protein and implemented it at a number of plants in Russia.
              This commercially available, proven technology makes it possible to obtain high-quality proteins from food processing industry waste (distilleries and breweries, grain elevators, dairies) and process feed, low-grade and non-grade grain and other plant raw materials (shorts, molasses, whey, plant biomass, etc.).
              This technology solves the most challenging environmental problems associated with recycling waste from the food processing and agricultural industries and utilizing it in the national economy. The technology also makes use of nanobiotechnology to obtain essential nutrients for humans, such as folic acid (boosts immunity to cancer), vitamin B12, lactate salts with trace elements, and high-quality dietary protein (instead of imported GMO soy).
              The proposed technology has no analogs in the world, is protected by patents and is based entirely on domestic equipment.
              Large-scale implementation of this technology will allow alcohol manufacturers to carry out cost-effective recycling of waste products, and enable agricultural producers to obtain high-quality Russian-made feed protein to replace foreign GMO soy in domestic feeds.
              These products have good export potential.
              Bioprotein has a full set of permits, technical and design documentation for immediate rollout of this technology.

              Full details Contact close
            • ToysCollectorToysCollector

                Toys-collector main serve for toy enthusiasts and distributor,we professional to supply Transformer,Original Car Model, UAV,Autobots and so on by wholesale and retail. And freeshipping online store.If you are interesed in this kind of toys,please feel free to contact us,or log in our website to have a look first:

                Full details Contact close
              • Amylase assay hemolysis interference-freeAmylase assay hemolysis interference-free

                  Although the assessment of α-amylase is an essential part of the diagnostic workout of several pancreatic and extra-pancreatic disorders, its enzymatic activity is significantly reduced in the presence of cell-free hemoglobin such as in samples with spurious hemolysis, due to chemical and spectrophotometric interference. We developed a new reagent that provides reliable results on hemolyzed biological specimens.
                  The clinical applications of the experimental reagent include α-amylase assessment in hemolyzed samples, in urine and other biological fluids contaminated with lysed erythrocytes, or in patients under frequent transfusions and hemoglobin-based blood substitutes therapy. The formulation of this reagent could be adapted for other clinical chemistry or immunochemistry assays.
                  See publication at:

                  Full details Contact close
                • CHITINASE ACHITINASE A

                    Chitinases are proteins, that are found in different organisms such as viruses, bacteria, plants, insects, and mammals. They are responsible for the hydrolysis of chitin, which builds, inter alia, external skeletons of insects, arachnids, crustaceans, cell walls of fungi, algae, bacteria. The prevalence of the described compounds is one of the strengths of the present invention. The present invention describes an application of chitinase A, which belongs to the family Baculoviridae.

                    The possibility of using chitinase A and chitin derivatives in:
                     agriculture as an environmentally friendly bioinsecticide, replacing pesticides;
                     food processing as a natural preservative;
                     pharmaceutical industry as a formulation of a bactericide and fungicide;
                     pharmaceutical industry as potential cholesterol-lowering agents;
                     the energy industry with the acquisition of new, alternative and renewable energy.
                    Methods of chitinase purification, used so far, consisted of multi-stage and expensive procedures. Affinity chromatography was also used with so-called affinity tags. These tags could interfere with the functions of chitinase, and their cut-off was associated with the next step of digestion and purification.
                    The proposed method of chitinase A purification using affinity chromatography with the involvement of G proteins is fast and efficient single-step.
                    Affinity chromatography exploits the ability of proteins to specific bonds, in this case, chitinase A and protein G. This protein is derived from bacterial cell walls of the genus Streptococcus and it is now commonly used in affinity. This protein complex of chitinase A with protein-G is dissociated in aqueous solution with a low pH. This allows to extract chitinase A. What is important, an acidic environment does not affect the functionality of chitinase. Chitinase retains high biological activity even at pH = 2.

                    New method of chitinase A purification by affinity chromatography is the subject of a patent application, and the invention is still under development by scientists from the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University.
                    Currently the Centre for Innovation, Technology Transfer and University Development (CITTRU) is looking for the entities interested in the commercial applications of the described solution. CITTRU is looking for the business partners for joint research and development projects involving the above research topic.

                    Full details Contact close